Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of QLC7401 in adults with inadequately controlled elevated LDL-C on background lipid-lowering therapy
CTR20260169Phase 3Active
- Sponsor
- Suzhou Ribo Life Science Co., Ltd.
- Start
- Mar 2026
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Peptide-Drug Conjugates → Peptide Conjugates → Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of rbd7022 in hypercholesterolemia, combined dyslipidaemia, sponsored by Suzhou Ribo Life Science Co., Ltd.. Started Mar 2026; status: active.
02
Drugs
rbd7022
03
Conditions
hypercholesterolemiacombined dyslipidaemia
Beyond the preview
Go deeper on CTR20260169.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260169.